Globe Life is a steady compounder with improving health growth, strong cash generation, and a valuation that still looks reasonable versus earnings power.
Globe Life(GL) looks like a disciplined compounder rather than a flashy growth story. The core case rests on three hard facts: trailing EPS of $14.45, forward EPS expectations of $15.64 for 2026 and $16.58 for 2027, and a valuation of 12.8x trailing earnings and 11.8x forward earnings. That setup matters because the business is still growing. Revenue rose 5.4% YoY, earnings grew 12.6% YoY, Q1 2026 premium revenue increased 6% to $1.27B, and management raised full-year 2026 net operating EPS guidance to $15.40 to $15.90.
The investment appeal is straightforward. Globe Life serves lower-middle and middle-income households through a distribution model that combines exclusive agencies, direct-to-consumer marketing, and independent agents. That model has produced durable underwriting profits, free cash flow of $1.54B, ROE of 20.5%, and a 10.73% FCF yield. At the same time, the stock still trades below the $188.55 analyst target and below many quality financials on earnings multiple alone.
The main caution is that this is still an insurer, not a software company wearing a suit. Results depend on lapse behavior, claims trends, reserve assumptions, agent recruiting, and investment portfolio discipline. Management also acknowledged elevated lapse rates versus pre-pandemic levels and a Q1 2026 agent count decline of 4% at American Income Life. Those issues do not break the thesis, but they explain why Globe Life(GL) deserves a measured Buy rather than an aggressive top-shelf rating.
Globe Life Inc. is a U.S. life and supplemental health insurer headquartered in McKinney, Texas. The company was founded in 1900, trades on the NYSE under GL, and operates through Life Insurance, Supplemental Health Insurance, and Investments. It had 3,695 employees at year-end 2025 and engages more than 17,000 independently contracted insurance agents.
The company focuses on lower-middle and middle-income families, a segment management describes as underserved. Its product set includes whole life, term life, juvenile life, Medicare Supplement, accident, cancer, critical illness, heart, intensive care, final expense, mortgage protection, and hospital insurance. Distribution runs through direct-to-consumer channels, exclusive independent agents, general agency independent agents, and brokers.
Scale is meaningful in this niche. The 2025 investor deck showed 17.2M in-force policies, $4.89B of total premium revenue, and 17,304 agents across the system. Market capitalization stands at $14.35B, which places Globe Life(GL) in a useful middle ground: large enough to benefit from scale and data, but still focused enough that operational improvements can move the needle.
Globe Life’s business is still primarily a life insurer, but health is becoming a more important growth engine. In 2025, the Life Segment generated $3.36B of revenue, or 68.8% of segment total, while the Health Segment generated $1.53B, or 31.2%. In 2024, the mix was 69.9% life and 30.1% health. That shift is small, but it points in the right direction because health has been growing faster.
Q1 2026 made that split even clearer. Life premium revenue increased 3% to $853.2M, while health premium revenue rose 13% to $416.9M. Total premium revenue reached $1.27B, up 6% YoY. Life underwriting margin was $349M, up 3%, and health underwriting margin was $95M, up 12%. In plain English, life remains the ballast and health is providing more of the acceleration.
Within life, American Income Life remains the heavyweight. In Q1 2026, AIL life premiums rose 5% to $459M and life underwriting margin increased 7% to $209M. Liberty National added another $100M of life premium, up 4%, with underwriting margin up 11% to $35M. Direct-to-consumer life premiums slipped about 1% to $244M, but underwriting margin increased 15% to $74M, which matters more than volume alone.
Within health, Family Heritage and United American stood out. Family Heritage health premiums increased 10% to $123M and health underwriting margin rose 11% to $44M. United American health premiums jumped 22% to $194M, while health underwriting margin improved to $5M from roughly $1M a year earlier. That margin is still thin, but the growth is real and management tied it to Medicare Supplement momentum and worksite business expansion.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The flagship product family is traditional whole life sold into the company’s core demographic. The 2025 10-K showed whole life represented 71% of life annualized premium in force, or $2.42B out of $3.42B total life premium in force. Term accounted for 22%, or $753.8M, while other life products made up 6%. That concentration is important because it shows Globe Life(GL) is not chasing every shiny product category. It is leaning into a product it understands deeply.
The scale of that franchise is hard to ignore. Globe Life reported 9.09M traditional whole life policies in force in 2025 with an average face amount of $16.5K. Across all life products, policy count was 14.28M with an average face amount of $16.2K. These are modest-sized policies sold at large scale, which fits the company’s lower-middle and middle-income focus. It is an assembly-line insurance model, and that is not an insult. In this business, repeatability is a moat.
On the health side, Medicare Supplement is the standout growth product. In 2025, Medicare Supplement represented $752.7M of annualized premium in force, or 46% of total health premium in force. Limited-benefit plans made up the other 54% at $897.0M. Management said Q1 2026 health growth benefited from strong Medicare Supplement sales and about $65M of additional premium from approved rate increases that will be received during 2026, mostly in the last three quarters.
That combination makes sense. Life products provide persistence and underwriting margin, while Medicare Supplement adds a faster growth lane. The product mix is not glamorous, but it is practical, and practical products often age better than fashionable ones.
Globe Life’s moat is built on specialization, distribution, and operating discipline. The company has spent decades serving the same demographic with similar products, which gives it a long history of underwriting and lapse data. Management argues that this helps pricing, underwriting, and retention. The 10-K also states Globe Life competes effectively in part because it operates at lower policy acquisition and administrative expense levels than peers.
Technology is becoming the next layer of that advantage. In Q1 2026, management said expanded AI applications should help lower the administrative expense ratio over time. Administrative expenses were 7.4% of premium in Q1 2026, versus 7.3% a year earlier, and management said it is targeting movement closer to 7% over the next few years. That is not a moonshot. It is a basis-point story. But in insurance, basis points compound into real shareholder value.
Management also tied technology to agent productivity and retention. At American Income Life, net life sales rose 3% despite a 4% decline in average producing agents, which management attributed to improved productivity. Direct-to-consumer lead generation is also feeding agency channels, and the company expects DTC to increase leads generated for its three exclusive agencies by 5% to 10% during 2026. That cross-channel support is a real advantage because it lets Globe Life(GL) use one distribution engine to strengthen another.
Capital allocation is another competitive edge. In Q1 2026, the company repurchased 1.4M shares for $205M at an average price of $141.24 and returned about $225M to shareholders including dividends. When a business with a 10.73% FCF yield buys back stock at 11x to 12x forward earnings, that is not financial theater. It is rational capital recycling.
An insurer does not have a classic supply chain, but it does have an operating chain: recruit agents, generate leads, underwrite policies, collect premiums, process claims, invest float, and manage capital. Globe Life(GL) has built that chain around a mix of exclusive agencies, direct marketing, and independent agents. The system is designed for high-volume, relatively small-ticket policies, which is why process efficiency matters so much.
On the operating side, Q1 2026 administrative expenses were $94M, up about 8% YoY, and 7.4% of premium. Management expects full-year administrative expenses to run at about 7.3% of premium. The company believes AI and workflow automation can improve onboarding, training, claims review, customer service, and underwriting. That is a sensible target because Globe Life processes a large number of applications, service calls, and claims.
On the investment side, the company invested $419M in fixed maturities during Q1 2026 at an average yield of 6.23%, average rating of A, and average life of 42 years. It also invested about $147M in commercial mortgage loans and other long-term investments with debt-like characteristics. Total invested assets were $22B, including $19.1B of fixed maturities at amortized cost, with $18.6B investment grade and an overall portfolio rating of A-.
The portfolio is conservative by design. Below-investment-grade bonds were just 2.7% of fixed maturities, and BBB bonds were 41% of the fixed maturity portfolio, down from 45% a year earlier and the lowest level since 2003. Management also said total exposure to BBB and below-investment-grade securities as a percent of equity excluding AOCI is at its lowest level in more than 25 years. That matters because insurers can look safe right up until they are forced to realize losses. Globe Life(GL) is trying hard not to be that insurer.
Globe Life operates in U.S. life and supplemental health insurance, with a particular focus on lower-middle and middle-income households. Management describes that market as the largest segment of the population and significantly underserved. The company’s own footprint supports that claim: 17.2M in-force policies, $4.9B of premium revenue in 2025, and a broad multi-channel distribution platform.
Industry growth is not explosive, but it is durable. External market research cited in the research set estimated the U.S. life insurance market at $0.78T in 2024, rising to $1.16T by 2030, and the U.S. health and medical insurance market at $1.65T in 2026, rising to $2.15T by 2031. Globe Life(GL) does not need heroic market growth to win. It needs steady penetration in a large customer base and disciplined execution in Medicare Supplement and supplemental health.
The strongest near-term market tailwind is Medicare Supplement. Management said United American benefited from continued movement of Medicare beneficiaries from Medicare Advantage to Medicare Supplement, and approved rate increases are expected to add about $65M of premium during 2026. That is a concrete catalyst, not a hand-wave. It also helps explain why management expects health premium growth of 14% to 17% for the full year, far above life growth of 3% to 3.5%.
The market backdrop also favors companies with efficient distribution. Globe Life’s direct-to-consumer plus exclusive agency model gives it reach into customers who may not be served well by more advice-heavy or high-balance insurance models. In a market where affordability matters, cost discipline is a product feature even if it never appears on the brochure.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Globe Life’s customer base is unusually specific for a public insurer. The company targets lower-middle and middle-income families, working households, Medicare beneficiaries, and buyers seeking basic protection products rather than wealth-transfer or investment-heavy policies. That focus shapes everything from product design to policy size to distribution strategy.
The average face amount data makes that clear. Traditional whole life policies averaged $16.5K in face amount in 2025, term policies averaged $15.1K, and all life policies averaged $16.2K. These are not jumbo policies sold to affluent households. They are practical protection products sold at scale to customers who care about affordability, convenience, and trust.
This customer profile brings strengths and risks. The strength is that basic protection demand can remain resilient across cycles. Management said the business has been resilient through different economic environments and produced double-digit growth in net operating income per share in 7 of the last 8 quarters. The risk is affordability pressure. On the Q1 2026 call, management said lapse rates are expected to remain elevated versus pre-pandemic levels because of economic stress and overall price inflation affecting policyholders.
That trade-off is central to the stock. Globe Life(GL) serves a durable market, but not an easy one. It is selling financial protection to households that feel inflation first and hardest. The company’s long history in that segment is an advantage, but it does not repeal arithmetic.
Globe Life says no single company dominates its life or health markets, and that sounds right. The relevant competitor set varies by product and channel. In supplemental health, Aflac is a natural comparison. In Medicare Supplement, Mutual of Omaha is relevant. In individual life and middle-income distribution, Primerica, New York Life, Northwestern Mutual, and other life carriers matter depending on the product lane.
Globe Life’s edge is not breadth. It is focus. The company competes through policyholder service, price, product design, and sales effort, but the real differentiator is its low-cost operating model and specialized distribution. The 10-K states the company can maintain competitive rates while preserving higher underwriting margins because it operates at lower acquisition and administrative expense levels than peers.
That said, the company is less diversified than mega-cap insurers. It is concentrated in basic protection life and supplemental health, which means fewer offsetting revenue streams if one product line slows. Direct-to-consumer life is also more competitive, and management has acknowledged that channel faces more active shopping behavior. The company’s answer is to use DTC not just as a sales channel but as a lead engine for agencies, which is a smart way to turn a competitive channel into a support function.
Without peer-multiple data, the cleanest competitive conclusion is operational rather than statistical: Globe Life(GL) has outgrown many expectations through underwriting discipline, health momentum, and buybacks, but it still has to prove that agent recruitment and persistency can stay healthy enough to support that performance.
The macro picture for Globe Life(GL) is mixed but manageable. Higher interest rates support investment income, and that is showing up in the numbers. In Q1 2026, net investment income rose 3% to $290M, excess investment income increased to $37M, and the earned yield on total long-term invested assets was 5.5%. Management expects full-year earned yield on long-term investments between 5.45% and 5.5%, with new investments across asset classes at average yields of 6.3% to 6.5%.
The other side of that coin is unrealized bond losses. Management reported a $1.6B net underlying loss position in the fixed maturity portfolio due to market rates being above the book yield on holdings. The company said it is not concerned because it has both the intent and ability to hold investments to maturity. That is credible given the long duration of liabilities and strong underwriting profits, but it remains a reminder that insurers live in the spread business whether they like the label or not.
Inflation is a more direct pressure point on customers. Management explicitly cited economic stress and overall price inflation as reasons lapse rates remain elevated versus pre-pandemic levels. For a company serving working-class households, that is a real macro sensitivity. On the other hand, the same environment can support demand for affordable protection products, especially in health categories where out-of-pocket risk remains a concern.
Geopolitical exposure is limited. Globe Life’s core business is U.S.-focused, though it has operations in Canada, New Zealand, and Bermuda. The more relevant external factor is regulation. Insurance remains heavily supervised at the state level, and Globe Life also formed Globe Life Re Ltd. in Bermuda in 2025, which is subject to Bermuda Monetary Authority oversight. That structure can support capital efficiency, but it also adds a layer of regulatory complexity.
Globe Life’s balance sheet earns an A- thanks to $1.54B in free cash flow, a 10.73% FCF yield, and ROE of 20.5%, though insurer-specific risks still matter.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue rose 5.4% year over year and Q1 2026 premium revenue climbed 6% to $1.27B, with health premiums up 13% and life premiums up 3%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 net operating EPS guidance to $15.40-$15.90, while forward EPS is expected to reach $15.64 in 2026 and $16.58 in 2027.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Globe Life trades at 12.8x trailing earnings and 11.8x forward earnings, below the $188.55 analyst target and still modest for a high-ROE insurer.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s price framework puts the Buy level at $155 and the Hold level at $182, with the stock currently viewed as attractive below the fair value estimate.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Globe Life(GL) is not the kind of stock that wins attention by being loud. It wins by being repeatable. The company has a focused niche, durable underwriting economics, a conservative investment posture, and a management team still buying back stock aggressively when prices are favorable. Q1 2026 reinforced that pattern with 6% premium growth, 12% operating EPS growth, stronger health momentum, and higher full-year guidance.
The risks are real. Lapse rates remain elevated versus pre-pandemic levels, American Income Life agent count declined 4% in Q1 2026, and earnings are still shaped by assumption updates and claims trends. Insider activity also skews toward selling, and the company is not immune to regulatory, reputational, or macro pressure. Those are reasons to stay disciplined on entry price, not reasons to dismiss the business.
For a moderate-risk investor, the case comes down to quality at a fair price. Globe Life(GL) offers solid profitability, visible EPS growth, and shareholder-friendly capital allocation without demanding a premium valuation. With a fair value estimate of $182, the stock looks attractive below that level and especially compelling on meaningful pullbacks.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Globe Life is a disciplined insurer with steady premium growth, strong underwriting margins, and meaningful buyback support. The stock still looks undervalued relative to its earnings power and 2026 guidance.
Globe Life Inc. (GL) falls sharply in after-hours trading, erasing a chunk of recent gains near its 52-week high. The move appears tied more to earnings positioning and profit-taking than to a fresh company-specific headline, leaving investors focused on the upcoming April 22 report.
Intuitive Surgical, Inc. (ISRG) drops after investors reassess its post-earnings growth outlook. Despite strong Q2 results, slower procedure growth, tariff pressure, and a premium valuation are weighing on the stock.